Quantum BioPharma (NASDAQ: QNTM) is advancing its multiple sclerosis therapy candidate LUCID-MS, which targets demyelination and aims to protect or restore myelin integrity. The company was featured in a recent article discussing its progress, reporting that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated. These results support the company's move into patient-focused studies.
In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, clearing the path for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation. To strengthen operational support for the program, Quantum BioPharma plans to partner with Allucent and engage neurological specialists.
Multiple sclerosis is a chronic neurodegenerative disease characterized by the destruction of myelin, the protective sheath surrounding nerve fibers. Current treatments primarily focus on modulating the immune system to reduce inflammation, but they do not effectively repair existing damage. LUCID-MS, developed through Quantum BioPharma's wholly owned subsidiary Lucid Psycheceuticals Inc., is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
The implications for patients and the industry are significant. If Phase 2 trials confirm efficacy, LUCID-MS could become a first-in-class therapy that not only halts disease progression but also promotes repair of damaged myelin, potentially reversing disability. For investors and business leaders, Quantum BioPharma's progress represents a high-stakes opportunity in the neurodegenerative disease market, which is expected to grow substantially as the population ages. However, drug development carries inherent risks, and the company notes forward-looking statements involve uncertainties, including those detailed in its SEC filings.
Quantum BioPharma is also building a broader portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse. The company retains a 19.84% stake in Unbuzzd Wellness Inc., which markets an over-the-counter version of unbuzzd, and receives royalty payments of 7% of sales until $250 million, then 3% in perpetuity. Quantum BioPharma retains full rights to develop pharmaceutical and medical uses of similar products.
For more details, the full article is available at https://ibn.fm/AUhNl. Updates on QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
